Wistar Institute Wistar Institute Spinout Isoma Diagnostics Secures Seed Funding Isoma, which launched last year, will use the funds to develop and clinically validate a molecular test for stratifying glioblastoma patients. Genetic, Genomic Profiles Point to Potential Utility of Melanoma Xenograft Collection Investigators have established hundreds of patient-derived xenografts, cell lines, and tumor samples, which appear to represent a wide range of melanoma molecular subtypes. OncoCyte Lung Cancer Test Validation Data Bodes Well for Launch This Year Premium The company has achieved even higher specificity than earlier data demonstrated, and is now building up its sales and marketing infrastructure for the planned launch of its lung cancer test. Wistar, OncoCyte Ramp Up Efforts to Commercialize Lung Nodule Classifier Test Next Year Premium OncoCyte is proceeding full-steam ahead on commercializing the gene expression-based test, pursuing CLIA certification and a Q2 2017 launch. Wistar Institute, Graham Cancer Center Partner for Gene Editing in Cancer Research The partnership will place the Graham Cancer Center's Gene Editing Institute under the purview of the Wistar Institute's Molecular Screening Facility. Mar 10, 2016 PhoreMost, Wistar Institute to Collaborate on Novel Drug Target Discovery Feb 12, 2016 Expression of Gabra3 Activates AKT Pathway to Promote Breast Cancer Metastasis, Study Finds Jan 27, 2016 OncoCyte Acquires Rights to Lung Cancer Test from Wistar Aug 18, 2015 Wistar Institute, OncoCyte Expand Lung Cancer Dx Collaboration Mar 11, 2015 Wistar Receives $1.1M Award to Create Breast Cancer Research Consortium Sep 16, 2014 Wistar, Penn Win $12.1M in NCI Funds for Melanoma Studies Feb 24, 2014 NCI Recommends $14.9M Renewal for Wistar's Shared Resources Cores Oct 15, 2013 OncoCyte, Wistar to Develop Gene Expression-based Lung Cancer Diagnostic Jul 9, 2013 IP Watch: MDxHealth, GSK, Ambergen, Keygene, Bio-Rad, Illumina Among US Patent Winners Premium May 9, 2013 Wistar Team Finds New Role for ADAR1 in RNA-Induced Gene Silencing Premium Aug 28, 2012 Wistar Team Using $1M Grant to Develop Gene Expression Panel to Detect Early-Stage Lung Cancer Premium Aug 20, 2012 Wistar Wins $1M to Develop Early Lung Cancer Dx Sep 23, 2011 Wistar Breaks Ground on $100M Facility, Launches Capital Campaign Apr 15, 2009 Philly's University City Science Center Debuts $1.2M POC Fund for Academic Life-Sci Projects Premium Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.